Pyrrolotriazine kinase inhibitors

Details Pyrrolotriazine kinase inhibitors Pyrrolotriazine kinase inhibitors

2006-09-05

2006-09-05

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C514S243000

Reexamination Certificate

active

07102002

ABSTRACT:
The present invention provides compounds of formula I,and pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

REFERENCES:
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 6787545 (2004-09-01), Ohtani et al.
patent: 6867300 (2005-03-01), Godfrey, Jr. et al.
patent: 6869952 (2005-03-01), Bhide et al.
patent: 6908916 (2005-06-01), Mastalerz et al.
patent: 6916815 (2005-07-01), Vite et al.
patent: 2003/0232831 (2003-12-01), Dyckman et al.
patent: 2003/0232832 (2003-12-01), Lombardo et al.
patent: 2004/0063707 (2004-04-01), Bhide et al.
patent: 2004/0063708 (2004-04-01), Bhide et al.
patent: 2004/0077858 (2004-04-01), Bhide et al.
patent: 2004/0229877 (2004-11-01), Leftheris et al.
patent: 0 713 876 (1996-05-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 02/40486 (2002-05-01), None
patent: WO 03/090912 (2003-11-01), None
patent: WO 2004/009784 (2004-01-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, 1004-1010, 1996.
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York 1996, pp. 451 and 596.
Mass, R. D., Int. J. Radiation Oncology Bio. Phys. vol. 58(3): 932-940, 2004.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
And Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.
U.S. Appl. No. 60/620,784, filed Oct. 21, 2004, Gavai et al.
U.S. Appl. No. 11/008,719, filed Dec. 9, 2004, Swaminathan et al.
U.S. Appl. No. 11/019,899, filed Dec. 22, 2004, Gavai et al.
U.S. Appl. No. 11/019,901, filed Dec. 22, 2004, Fink et al.
U.S. Appl. No. 11/157,460, filed Jun. 21, 2005, Gavai et al.
Ewald, H. et al., “Reaktionen von 1,2,4-Triazinen mit Acetylendicarbonsäure-dimethylester”, Liebigs Ann. Chem., pp. 1718-1724 (1977).
Hunt, J.T et al., “Discovery of the Pyrrolo[2,1-f][1,2,4]triazine Nucleus as a New Kinase Inhibitor Template”, J. Med. Chem., vol. 47, No. 16, pp. 4054-4059 (2004).
Migliara, O. et al., “Synthesis of a New Bridgehead Nitrogen Heterocyclic System. Pyrrolo[2,1-f]-1,2,4-triazine Derivatives”, J. Heterocyclic Chem., vol. 16, pp. 833-834 (1979).
Neunhoeffer, H. et al., “Cycloadditionen mit Methoxy- und Dialkylamino-1,2,4-triazinen”, Liebigs Ann. Chem., pp. 1413-1420 (1977).
Patil, S.A. et al., “Synthesis of Pyrrolo[2,1-f][1,2,4]triazine Congeners of Nucleic Acid Purinesviathe N-Amination of 2-Substituted Pyrroles”, J. Heterocyclic Chem., vol. 31, pp. 781-786 (1994).
Quintela, J.M. et al., “A Ready One-pot Preparation for Pyrrolo[2,1-f][1,2,4]triazine and Pyrazolo[5,1-c]pyrimido[4,5-e]-[1,2,4]triazine Derivatives”, Tetrahedron, vol. 52, No. 8, pp. 3037-3048 (1996).

Affiliated with

Also associated with

Rating

Pyrrolotriazine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolotriazine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolotriazine kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3531860